The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx).
 
Jianjun Gao
Travel, Accommodations, Expenses - AstraZeneca
 
Jose A. Karam
Honoraria - Pfizer; Roche/Genentech
Consulting or Advisory Role - Pfizer; Roche/Genentech
Research Funding - Mirati Therapeutics (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche/Genentech
 
Nizar M. Tannir
Honoraria - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Oncorena; Ono Pharmaceutical; Pfizer
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Mirati Therapeutics; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Onco Pharmaceuticals; Oncorena; Pfizer
 
Matthew T Campbell
Honoraria - Eisai; EMD Serono; Genentech/Roche; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Apricity Health; AstraZeneca; Eisai; EMD Serono; Genentech; Novartis; Pfizer
Research Funding - Exelixis
 
Rebecca Slack Tidwell
No Relationships to Disclose
 
Kamran Ahrar
No Relationships to Disclose
 
Priya Rao
No Relationships to Disclose
 
Chaan S. Ng
No Relationships to Disclose
 
Eric Jonasch
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Ipsen; Novartis; Peloton Therapeutics; Pfizer
Research Funding - Exelixis; Novartis; Peloton Therapeutics; Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Surena F. Matin
Honoraria - C-SATS; Peloton Therapeutics; Taris BioMedical; Urogen pharma
Consulting or Advisory Role - C-SATS; Peloton Therapeutics; Theracoat; Urogen pharma
Research Funding - AT&T
 
Amado J. Zurita
Honoraria - Exelixis; Janssen Oncology
Consulting or Advisory Role - Exelixis
Research Funding - Infinity Pharmaceuticals; Pfizer
 
Amishi Yogesh Shah
Honoraria - Eisai; Oncology Information Group
Research Funding - Bristol-Myers Squibb; Eisai; EMD Serono
 
Yu Shen
No Relationships to Disclose
 
Jorge M. Blando
No Relationships to Disclose
 
Luis M. Vence
No Relationships to Disclose
 
Sreyashi Basu
No Relationships to Disclose
 
Hao Zhao
No Relationships to Disclose
 
James Patrick Allison
Patents, Royalties, Other Intellectual Property - Inventor of a patent held by the University of California, Berkeley, and licensed to Bristol Meyers-Squibb; Inventor of a patent owned by Memorial Sloan-Kettering Cancer Center and licensed by Jounce Therapeutics
 
Christopher G. Wood
Honoraria - Pfizer
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Argos Therapeutics; Boehringer Ingelheim; GlaxoSmithKline; Ono Pharmaceutical; Pfizer
Travel, Accommodations, Expenses - Argos Therapeutics
 
Padmanee Sharma
Stock and Other Ownership Interests - Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); Codiak Biosciences; Codiak Biosciences (I); Constellation Pharmaceuticals; Forty Seven; Forty Seven (I); Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Jounce Therapeutics; Jounce Therapeutics (I); Marker Therapeutics; Marker Therapeutics (I); Neon Therapeutics; Neon Therapeutics (I); Oncolytics; Polaris; Polaris (I); TapImmune Inc.; TapImmune Inc. (I); Tvardi Therapeutics (I)
Consulting or Advisory Role - Amgen (I); Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); Bristol-Myers Squibb (I); Codiak Biosciences; Codiak Biosciences (I); Constellation Pharmaceuticals; Forty Seven; Forty Seven (I); Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Jounce Therapeutics; Jounce Therapeutics (I); Marker Therapeutics; Marker Therapeutics (I); Merck; Merck (I); Neon Therapeutics; Neon Therapeutics (I); Oncolytics; Pieris Pharmaceuticals; Polaris; Polaris (I); TapImmune Inc.; TapImmune Inc. (I); Tvardi Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)